PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32247597-1	2020	BACKGROUND: The aim of the study was to assess bioavailability aspects of tacrolimus formulations during conversion from twice-daily (TAC BID) to once-daily (TAC OD) formulation in 89 stable kidney transplant recipients.	Tacrolimus	74-84	BH3 interacting domain death agonist	Homo sapiens	138-141	
32247597-9	2020	CONCLUSIONS: Conversion from TAC BID to TAC OD is associated with a significant increase in tacrolimus dose during the first 3 months.	Tacrolimus	92-102	BH3 interacting domain death agonist	Homo sapiens	33-36